Are AstraZeneca plc & Thomas Cook Group plc ‘Screaming Buys’?

Should you buy AstraZeneca plc (LON: AZN) and Thomas Cook Group plc (LON: TCG) right now?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In the long run, all companies encounter highly challenging periods. They can be due to external factors such as a weakening in demand for a particular product or a slowdown in the wider economy. They can also be caused by internal challenges, such as poor planning and a strategy which ultimately leads to disappointing top and bottom line performance.

Either way, it normally has a very negative impact on a company’s share price and, while the effects can be horrific for investors, it also presents a very appealing buying opportunity. That’s because if the company can either adopt a better strategy or the external factors improve, capital gains could prove to be very enticing.

One company which has endured a very tough period is AstraZeneca (LSE: AZN). Its problems have largely been its own making, with the company failing to develop sufficient new drugs and put in place a suitable pipeline to overcome the inevitable loss of patents on key, blockbuster drugs. Furthermore, it also failed to use its cash in the most efficient manner; favouring a share buyback programme ahead of investing in research and development capabilities.

The result has been a severe decline in profitability, with AstraZeneca’s earnings per share expected to be just 62% of their 2011 level when the company reports its 2015 full-year results. However, AstraZeneca appears to now be making all of the right moves through which to mount a successful comeback, with an ambitious acquisition programme breathing new life into the company’s pipeline.

Clearly, it will inevitably take time to post positive profit growth. However, it seems likely to do so over the medium term which makes it current price to earnings (P/E) ratio of 16.1 seem hugely appealing.

Similarly, Thomas Cook (LSE: TCG) has also endured a troubled past, with the company becoming a loss-making entity in the period 2011 to 2014. This had a disastrous impact on the company’s share price, with it falling to a low of 13p in 2012 and there being major concerns about whether it would survive its difficult trading period.

However, now that the economic outlook is improved Thomas Cook is moving from strength to strength. Today’s results show that the company has made its first annual profit in five years despite the negative impact on demand for its holidays caused by the terrorist incidents of recent months. And, with the winter season already being 58% sold, it appears to be well-placed to deliver continued strong performance moving forward.

Looking ahead, Thomas Cook is forecast to increase its earnings by 28% next year which, alongside a P/E ratio of 9.4, puts it on a price to earnings growth (PEG) ratio of just 0.3. This indicates that its shares have very appealing capital gains prospects – especially since the UK and European economies are showing signs of life and are set to benefit from a continued loose monetary policy in future years.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

A senior man using hiking poles, on a hike on a coastal path along the coastline of Cornwall. He is looking away from the camera at the view.
Investing Articles

Buying 56,476 shares in this FTSE 100 dividend stock could double the State Pension

Harvey Jones crunches the numbers to show how much he needs to hold in one top dividend stock to generate…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

This FTSE 250 stock’s crashed 18% today! Is it too cheap to miss?

Vistry is one of the FTSE 250's worst-performing stocks, sinking by double-digit percentages on Wednesday (4 March). Is this a…

Read more »

ISA Individual Savings Account
Investing Articles

How much do I need in a Stocks and Shares ISA to earn a £100 monthly income?

A 6% dividend yield's enough to turn £20,000 into a £100 monthly income for investors using a Stocks and Shares…

Read more »

Calendar showing the date of 5th April on desk in a house
Investing Articles

It’s ISA time – but would your money work harder in a SIPP? I asked ChatGPT…

As the annual Stocks and Shares ISA deadline looms, Harvey Jones asks if investors would be better off putting money…

Read more »

Investing Articles

Up 42% in 12 months! Why I like this dividend share yielding 5%

This FTSE 100 dividend share has soared higher while still maintaining a dividend yield of 5%. Ken Hall takes a…

Read more »

Burst your bubble thumbtack and balloon background
Investing Articles

£15,000 invested in Helium One shares in December 2020 is now worth…

James Beard explains why loyal Helium One shareholders will be hoping the group can soon commercialise gas production.

Read more »

Departure & Arrival sign, representing selling and buying in a portfolio
Investing Articles

£1,000 now buys 264 shares in British Airways owner IAG. Worth it?

This time last week, IAG shares were flying high. However, in the blink of an eye, they’ve fallen about 16%.…

Read more »

Finger clicking a button marked 'Buy' on a keyboard
Investing Articles

A once-in-a-decade opportunity to buy BAE Systems shares ‘cheaply’?

BAE Systems shares are on the charge. Ken Hall investigates if this could be just the beginning for the FTSE…

Read more »